$28.78
3.34% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US68213N1090
Symbol
OMCL

Omnicell, Inc. Stock price

$28.78
-0.87 2.93% 1M
-13.04 31.18% 6M
-15.74 35.35% YTD
-1.95 6.35% 1Y
-82.89 74.23% 3Y
-35.94 55.53% 5Y
-7.63 20.96% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.93 3.34%
ISIN
US68213N1090
Symbol
OMCL
Sector
Industry

Key metrics

Market capitalization $1.35b
Enterprise Value $1.32b
P/E (TTM) P/E ratio 63.34
EV/FCF (TTM) EV/FCF 10.56
EV/Sales (TTM) EV/Sales 1.16
P/S ratio (TTM) P/S ratio 1.19
P/B ratio (TTM) P/B ratio 1.07
Revenue growth (TTM) Revenue growth 3.00%
Revenue (TTM) Revenue $1.14b
EBIT (operating result TTM) EBIT $12.56m
Free Cash Flow (TTM) Free Cash Flow $125.02m
Cash position $414.40m
EPS (TTM) EPS $0.45
P/E forward negative
P/S forward 1.19
EV/Sales forward 1.17
Short interest 7.50%
Show more

Is Omnicell, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Omnicell, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Omnicell, Inc. forecast:

5x Buy
56%
4x Hold
44%

Analyst Opinions

9 Analysts have issued a Omnicell, Inc. forecast:

Buy
56%
Hold
44%

Financial data from Omnicell, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,136 1,136
3% 3%
100%
- Direct Costs 645 645
2% 2%
57%
491 491
4% 4%
43%
- Selling and Administrative Expenses 301 301
30% 30%
27%
- Research and Development Expense 89 89
4% 4%
8%
101 101
31% 31%
9%
- Depreciation and Amortization 88 88
47% 47%
8%
EBIT (Operating Income) EBIT 13 13
162% 162%
1%
Net Profit 21 21
201% 201%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Omnicell, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omnicell, Inc. Stock News

Neutral
Business Wire
6 days ago
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Announces New Products for Perioperative and Clinic Settings.
Neutral
Business Wire
7 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Omnicell, Inc. (Nasdaq:OMCL), (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced the opening of its Innovation Lab, located at 1005 East St. Elmo Road in Austin, Texas. The facility will serve as a hub focused on addressing challenges along the medication and supply journey and developing new tech...
Negative
Seeking Alpha
13 days ago
Omnicell, Inc., a small cap medical technology solutions provider, posted its Q1 results Tuesday.  Both top and the bottom-line results beat the consensus. However, thanks to some new headlines and reduced forward guidance, OMCL shares sold off 15% in trading yesterday. A buying opportunity?  An analysis around Omnicell follows in the paragraphs below.
More Omnicell, Inc. News

Company Profile

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.

Head office United States
CEO Randall Lipps
Employees 3,670
Founded 1992
Website www.omnicell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today